#PREDICT trial investigates biomarker-guided treatment for advanced #ProstateCancer. Rana McKay, MD, FASCO UC San Diego and Alicia Morgans, MD, MPH Dana-Farber to discuss the PREDICT trial — a biomarker-driven approach for mCRPC patients post-ARPI. 💡 DNA and RNA profiling 🔍 Targeted arms:

📅 El 26/9/25 en Valencia celebramos la I Jornada de formación en investigación en oncología, ¿cómo diseñar un ensayo clínico? Investigación, estadística, financiación…, con enfoque práctico. ¡Trae tu propuesta y hazla crecer! #Oncología #Investigación guardconsortium.org/actividad/jorn…

‼️‼️ABSOLUTAMENTE RECOMENDABLE‼️‼️ Excelente iniciativa de nuestro Coordinador de GUO-AEU Daniel Pérez Fentes UNÍOS si podéis

¡Gracias a todos por el éxito del Mentorship Meeting! Y en especial a Pedro C Barata, MD MSc FACP por su apoyo y su implicación. Seguro que muchos futuros proyectos de GUARD Consortium salen de esta reunión. ¡Os esperamos mañana en el GUARD International Symposium!

STARTING NOW‼️#GUARDSymposium2025 Join us ONLINE for the GUARD Symposium🇪🇸 featuring interactive workshops where experts collaboratively discuss real-world genitourinary cancer cases. REGISTER👉 events.tacticsmd.net/guard-internat… ⭐️FREE VIRTUAL Admission for LMIC's & LATAM Colleagues⭐️

🌟SBRT in Renal Tumors 👨‍⚕️ Dr. Abrahams Ocanto – Radiation Oncologist #GUARDSymposium2025 Abrahams Ocanto OncoAlert 📌 IROCK pooled analysis (12 centers) ▪️ 223 patients ▪️ Median tumor size: 4 cm ▪️ 2-year local control: 97.8% 📌 FASTRACK II (non-randomized phase II) ▪️ 70

An AMAZING Start of #GUARDSymposium2025 in BEAUTIFUL MADRID SPAIN!! REGISTER👉 buff.ly/r4vwa6B STILL NOT TOO LATE TO JOIN US VIRTUALLY!!! ⭐️FREE VIRTUAL Admission for LMIC's & LATAM Colleagues⭐️ Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos

🌟Post-Adjuvant Relapse in Kidney Cancer 👨‍⚕️ Presented by Pedro C Barata, MD MSc FACP #GUARDSymposium2025 OncoAlert 📌 Key Questions in mRCC: ▪️ Start systemic therapy? ▪️ What to do with the primary tumor? ▪️ Deferred vs upfront nephrectomy (PROBE, SAMURAI trials) 📌 Upon progression

Excelente mesa de cáncer renal en el GUARD International Symposium. ¡Y esto solo acaba de empezar!

🌟 Adjuvant Therapy in Renal Cancer 👨‍⚕️ Presented by Javier Molina Cerrillo #GUARDSymposium2025 OncoAlert 📌 Current status: ▪️ Pembrolizumab (KN564) = approved, DFS+ but OS data immature ▪️ CheckMate 914 & PROSPER = negative ▪️ No predictive biomarkers ▪️ Ongoing: RAMPART, LITESPARK-022

LIVE DAY 1 #GUARDSymposium2025 Presentation by Dr. Paolo Castellucci🇮🇹 on Staging of localized high risk #ProstateCancer with PET PSMA PSMA PET/CT offers significant advantages in staging high-risk prostate cancer due to its superior accuracy in detecting both nodal and

Metastatic CSPC is changing and becoming personalised. The AMPLITUDE trial #GUARDSymposium2025 by AttardLab supporting PARPi in HRR/BRCA altered disease. PTEN and PSMA may also have a role for chemo and radioligands. A new era in prostate cancer OncoAlert

LIVE Day TWO #GUARDSymposium2025 Presentation by Dr. Joan Carles🇪🇸 Has precision medicine reached metastatic hormone-sensitive prostate cancer? Despite a general shift towards precision medicine in cancer treatment, which focuses on identifying genetic alterations crucial for

🌟🔵 Redefiniendo el cáncer de próstata metastásico hormonosensible Javier Puente OncoAlert #GUARDSymposium2025 🔹 El momento y la carga tumoral definen el pronóstico en mHSPC 🔹 La elección del tratamiento depende de la enfermedad, el paciente y el esquema 🔹 La terapia triple fue

🌟🔵 Perioperative IO in MIBC: where are we heading? Presentation by Dr. Andrea Necchi #GUARDSymposium2025 OncoAlert Advanced Prostate Cancer Consensus Conference 🌟Critical questions remain: pCR utility, timing, IO-only options 🔹 Neoadjuvant: better compliance, early systemic control & biomarker discovery

🌟🟠 Preservación vesical en CTVMI Presentado por Matt Galsky @MountSinaiCancer OncoAlert @GUARDConsortium #GUARDSymposium2025 👀 La selección de pacientes es clave. ¿Todo lo que puede hacerse, debe hacerse? 🔵 TURBT + tto sistémico enfrenta barreras históricas: falta de

LIVE Day TWO #GUARDSymposium2025 Presentation by Dr. Matt Galsky🇺🇸 How to select patients in whom we preserve the bladder without local treatment? Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido Javier Molina Cerrillo David Lorente

🌟🟠 Powerful insights by Syed A Hussain at GUARD Consortium #GUARDSymposium2025 OncoAlert 💡 One disease, many paths in mUCl 🔹 >50% of mUC patients receive no 1L treatment 🔹 High dropout rate despite multiple available options 🔹 Key decision drivers: efficacy,

🌟🟠 ¿Cómo tratar a los pacientes tras progresión a Enfortumab-Pembrolizumab? Presentado por Tom Powles en el #GUARDSymposium2025 OncoAlert 🧩 El escenario post EV+P está en evolución: los datos, la innovación y la precisión definirán el futuro. 🔵 Necesidad clínica no cubierta

LIVE DAY 2 #GUARDSymposium2025 Our OncoAlert 🚨Faculty Tom Powles 🇬🇧Discusses: How to treat Advanced #BladderCancer patients after progression to Enfortumab-Pembrolizumab? Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido